First patient dose in the Phase 1/2 clinical trial expected in mid-2023BOSTON, April 20, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics,…
Acquisition Transforms the Company into a Broader Pharmaceutical Company Spanning Multiple Sectors Company Announces Corporate Name Change to Underscore Broader…
WARMINSTER, Pa., April 20, 2023 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive…
ProgenaCare to commercialize coactiv+™ Antimicrobial Wound Gel in the U.S. wound care marketWINNIPEG, Manitoba, April 20, 2023 (GLOBE NEWSWIRE) --…
SCOTTSDALE, Ariz., April 20, 2023 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care…
Cuvrior™ now available in the US for the treatment of adult patients with stable Wilson disease who are de-coppered and…
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 20, 2023 –…
Application for $3M of non-dilutive funding for Phase 2a Alzheimer’s trial will be submitted in Q2 2023Tiziana guided by FDA…
MISSISSAUGA, Ontario, April 20, 2023 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator,…
CAMBRIDGE, Mass., April 20, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on…